Directorio
We are doing this study to see if the study drug, PT886, with or without chemotherapy and/or pembrolizumab, is a safe and effective option for gastric and pancreatic cancer. We are also trying to find the best dose of the study drug to use.
We are doing this study to see if the study drug, QTX3034, either with or without cetuximab, is safe and effective for treating KRAS G12D mutated cancer. We are also trying to find the best dose of QTX3034 to use.
We are doing this study to find out if an experimental drug called QTX3046 (the study drug) is a safe and effective option for KRAS G12D mutated cancer. We want to know how well it works on its own and in combination with a drug called cetuximab, and we are also trying to find the best dose of the study drug to use.
We are doing this study to find out if an investigational drug called QTX3544 (the study drug) is a safe and effective option for KRAS G12V mutated cancer. We want to know how well it works on its own and in combination with a drug called cetuximab, and we are also trying to find the best dose of the study drug to use.
We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.
We are doing this study to find out if an experimental drug called RO7589831 (the study drug) is a safe and effective option for cancers with solid tumors. We also want to find out what the best dose of the study drug is in this study.
Study of Combo of Anti-LAG-3 & Anti-PD-1 Antibodies in Subjects with Advanced or Metastatic Melanoma
We are doing this study to find the most effective, safe dose of a combination of the drugs fianlimab and ceminplimab. We want to know if this combination is an option for people with melanoma. We will compare how well this drug combination works to the usual treatment of relatlimab and nivolumab, which has the brand name Opdualag®.
If you choose to join this study, you will:
- Get 2-6 cycles of Inotuzumab Ozagamicin, lasting 1 month per cycle
- Get Methotrexate on day one during cycle 1 and on day 28 of cycles 2, 4 and 6
- Get about 3-5 mL of blood collected prior to treatment and at three time points during cycle 1 and 4 time points during cycle 2